^
Association details:
| Biomarker: | EGFR mutation + Chr 1p13.3-p13.1 |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer
Published date:
09/19/2023
Excerpt:
Within the EGFR-mutated group, patients with a gain in Chr 1p13.3-p13.1 exhibited poor TKI responses, a high relapse rate, and shortened PFS (P = 0.002).
DOI:
10.2147/PGPM.S418320
